Results 101 to 110 of about 28,066 (219)

Inhibiteurs de PCSK9 : futur traitement pour baisser le cholestérol?

, 2014
The achievement rate of recommended low-density lipoprotein cholesterol (LDL-C) targets of < 1.8 mmol/l for secondary prevention in very high risk patients is difficult.
Mach, F, Rodondi, Nicolas, Gencer, B
core  

Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9.

, 2009
BACKGROUND: We measured plasma PCSK9 concentrations in healthy men with a PCSK9 (proprotein convertase subtilisin/kexin type 9) loss-of-function variant (p.R46L), in statin-treated patients with a clinical diagnosis of familial hypercholesterolemia (FH ...
Cooper, JA, Li, KW, Konrad, RJ, Troutt, JS, Acharya, J, Scartezini, M, Neil, A, Humphries, SE, Whittall, RA, Neely, RD   +9 more
core   +1 more source

Toward Individualized Atherosclerosis Therapy: Clinical Endotypes, Programmable Therapeutics, and Delivery Constraints

Medicine Bulletin, EarlyView.
ABSTRACT Atherosclerosis remains the dominant substrate of atherosclerotic cardiovascular disease (ASCVD), yet recurrent events persist even when LDL cholesterol is driven to guideline targets, underscoring residual risk as a central limitation of contemporary prevention.
Yundong Peng, Rui Li, Huan Li, Jun Zhou, Xuanshi Liu, Guilherme Valente, Tataiana de Campos Melo, Sifan Chen, Lei Gu   +8 more
wiley   +1 more source

Prime editing in neuropsychiatric disorders: From mutation‐specific target selection to clinical translation

Neuroprotection, EarlyView.
Abstract Prime editing, a novel clustered regularly interspaced short palindromic repeats (CRISPR)‐based technology, fuses a reverse transcriptase (RT) to an engineered CRISPR‐associated protein 9 (Cas9) and uses a prime editing guide RNA (pegRNA)‐encoded template.
Tianshan Ji, Yuan Zhang, Jinyi Zhao, Yiping Lu, Chengkun Wang   +4 more
wiley   +1 more source

Autocrine effects of PCSK9 on cardiomyocytes

, 2020
Proprotein convertase subtilisin kexin type 9 (PCSK9) is in the focus of cardiovascular research due to its role in hepatic low density lipoprotein (LDL) clearance. However, extrahepatic expression of PCSK9 such as in cardiomyocytes and its regulation by
, Annemarie, Rohrbach, Susanne, Li, Ling, Schlüter, Klaus-Dieter, Kutsche, Hanna Sarah, Schreckenberg, Rolf, Weber, Martin, Schulz, Rainer   +7 more
core   +1 more source

Regulating Lipid Metabolism in Cancer: The Therapeutic Potential of Traditional Chinese Medicine

Phytotherapy Research, EarlyView.
By regulating the reprogramming of lipid metabolism in tumor cells, TCM provides a novel strategy for antitumor therapy with reduced toxicity and enhanced efficacy. ABSTRACT Lipid metabolic reprogramming is a key feature of tumor cells to adapt to the microenvironment and plays an important role in tumor growth, invasion, and metastasis.
Yufeng Gao, Huiming Huang, Xuejiao Wei, Xiaoxue Wang, Wanying Xie, Xinyu Qiu, Fei Wang, Zhuguo Wang, Ruoxin Zhang, Yilin Cai, Changhai Qu, Zhongdong Hu   +11 more
wiley   +1 more source

Common and Low-Frequency Genetic Variants in the PCSK9 Locus Influence Circulating PCSK9 Levels

, 2012
Objective- Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a circulating protein that influences plasma low-density lipoprotein concentration and susceptibility to coronary heart disease.
P. Eriksson, F. M. van 't Hooft, de Faire, Ulf, B. Gigante, Eriksson, Per, J. S. Troutt, Syvänen, Ann-Christine,, Troutt, Jason S., van 't Hooft, Ferdinand M., U. de Faire, Chernogubova, Ekaterina, R. J. Konrad, Franco-Cereceda, Anders, Malarstig, Anders, M.-L. Hellenius, Strawbridge, Rona, Hellenius, Mai-Lis, A.-C. Syvanen, A. Franco-Cereceda, Gigante, Bruna, Mahdessian, Hovsep, H. Mahdessian, R. Strawbridge, S. Krapivner, Konrad, Robert J., A. Malarstig, Krapivner, Sergey, Hamsten, Anders, E. Chernogubova, A. Hamsten   +29 more
core   +1 more source

Different blood lipid profiles and their role in cardiometabolic disease progression: A comparative study between an East Asian and European Large Prospective Cohorts

VIEW, EarlyView.
In this study, we analyzed data from the Kailuan study in China (N = 95,711) and the UK Biobank (N = 388,317), comprising adults free of CMDs at baseline. The results demonstrated distinct, population‐specific patterns regarding how blood lipids influence the transition from a healthy state to incident CMDs and subsequently to CMM.
Lili Huang, Zhe Huang, Fandi Mo, Xinming Xu, Yuchong Zhang, Xinqiang Ma, Tingting Geng, Chengkai Hu, Shiyi Li, Genmao Cao, Hanji Fang, Shouji Qiu, Zhicheng Zhang, Sun Liang, Xiang Gao, Shouling Wu, Lixin Wang   +16 more
wiley   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source